U.S. Transportation Stock News

In late June 2026, Recursion Pharmaceuticals, Inc. was added to several Russell value and small-cap benchmarks, widening its footprint across key US equity indices and increasing its visibility to institutional and index-tracking investors. This broader index inclusion, combined with growing attention on its AI-native drug discovery platform and advancing clinical pipeline, is subtly reshaping how the market weighs Recursion’s mix of high innovation, high costs, and partnership-driven...

Index additions and sentiment shifts around DLocal DLocal (NasdaqGS:DLO) has just been added to a wide set of Russell indices. This development coincides with stronger investor interest, upbeat analyst coverage, and higher expectations for its emerging markets payments business. This combination of index inclusions and research attention has arrived alongside active insider trading plans and options for insiders to convert Class B into Class A shares. This gives investors several moving parts...

Attention around Braze (BRZE) has picked up after Goldman Sachs initiated coverage, pointing to accelerating demand for the company’s AI powered customer engagement tools, along with its recent fiscal first quarter 2027 results and billings growth. See our latest analysis for Braze. At a share price of $24.15, Braze has seen short term momentum pick up, with a 7 day share price return of 15.16% and a 90 day share price return of 7.86%. However, the year to date share price return is down...

Hamilton Lane stock has had a tough year, with a steep decline in the share price set against valuation checks that now lean toward the shares looking cheap on several measures. With the company still active in raising and deploying capital, investors are weighing whether the current level reflects a reset in expectations or a potential mispricing. Over the past 12 months, Hamilton Lane shares have fallen 42.4%, which naturally raises the question of whether sentiment has moved further than...

Tariffs back in the headlines can rattle import heavy retailers, but they can also shine a light on companies that look better prepared for higher trade frictions. With potential 10% to 12.5% duties on goods from 60 countries and renewed global tariffs on the table, some large U.S. consumer retailers with strong North American focus and healthier balance sheets may be positioned to handle higher costs more effectively than peers. This article walks through 3 stocks from a U.S. Import...

Boyd Gaming Corporation was recently removed from the Russell 1000 Dynamic Index and earlier appointed retail veterans Stacia J. Andersen and George C. Roeth to its Board of Directors, bringing experience from PetSmart, Abercrombie & Fitch, Target, Clorox, and other consumer-facing companies. The index removal may influence institutional ownership patterns, while the new directors’ consumer-brand expertise could shape how Boyd Gaming refines its customer focus and growth initiatives. Next,...

Construction Partners stock has delivered very strong returns over the past three years, yet the current valuation picture is mixed, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while the broader checks flag the shares as far from a clear bargain. Construction Partners has returned about 271.7% over the past three years, which puts extra focus on whether recent gains already reflect the business outlook. Strong demand across public infrastructure...

Over the last 7 days, the United States market has remained flat, yet over the past 12 months, it has experienced a notable rise of 20%, with earnings forecasted to grow by 18% annually. In such an environment, identifying stocks that may be priced below their estimated value can offer potential opportunities for investors seeking to capitalize on future growth prospects.

The United States market has remained flat over the last week but is up 20% over the past year, with earnings projected to grow by 18% annually in the coming years. In this environment, identifying growth companies with strong insider ownership can be a strategic approach as it often indicates confidence from those closest to the business and potential alignment with shareholder interests.

In the last week, the United States market has stayed flat, but it is up 20% over the past year, with earnings expected to grow by 18% per annum over the next few years. Investing in penny stocks—though often considered a niche area—can still present growth opportunities, especially when these stocks are supported by strong financial health. Here, we explore several intriguing penny stocks that stand out for their financial strength and potential for long-term growth.

Legal action puts fresh focus on First BanCorp stock First BanCorp (NYSE:FBP) is in the spotlight after investors digested news of a lawsuit in the Southern District of New York related to banking services for Jeffrey Epstein, following a U.S. Virgin Islands acquisition. See our latest analysis for First BanCorp. The legal headlines arrive after a strong run in First BanCorp’s stock, with a 30 day share price return of 8.96% and a 90 day share price return of 21.73%. The 1 year total...

In late June 2026, Valmont Industries, Inc. (NYSE: VMI) was removed from both the Russell 1000 Defensive Index and the Russell 1000 Value-Defensive Index, shifting its representation in key benchmark measures used by many institutional investors. At the same time, Valmont appeared in a GARP-style screen highlighting its earnings strength and financial quality, putting renewed focus on the company’s fundamentals despite its index removals. We’ll now examine how Valmont’s index removals,...

Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals (NasdaqGS:CRNX) in an all cash deal valued at about US$10b. The boards of both companies approved the transaction unanimously. The deal is expected to close in Q3 2026, subject to regulatory and Crinetics shareholder approvals. Crinetics Pharmaceuticals focuses on endocrine diseases, an area where larger drug makers have been looking to expand their presence. Vertex is set to add Crinetics' pipeline and clinical expertise to...

In late June 2026, Sarepta Therapeutics reported that the FDA accepted for filing supplemental New Drug Applications to convert accelerated approvals for its Duchenne muscular dystrophy therapies AMONDYS 45 and VYONDYS 53 into traditional approvals, supported by Phase 3 ESSENCE data and extensive real‑world evidence. Although the ESSENCE trial did not meet its primary endpoint, treatment-favoring trends, long-term safety data and real-world functional benefits could materially influence how...

Arrow Electronics (ARW) has been removed from both the Russell 1000 Value Defensive Index and the Russell 1000 Defensive Index, a move that can affect how certain rules based and benchmark aware investors view the stock. See our latest analysis for Arrow Electronics. Despite being dropped from the Russell 1000 Value Defensive and Russell 1000 Defensive indices, Arrow Electronics’ recent performance has been mixed, with the share price showing a 33.9% 90 day share price return and a 75.0% year...

CVR Energy, Inc. recently appointed Richard Roberts as Interim Chief Financial Officer and Vice President of Financial Planning & Analysis and Investor Relations, making him the principal financial officer after a tenure in various finance roles since 2019. Roberts’ background in both internal finance leadership and external equity research across refining, integrated oil and midstream adds an unusually broad perspective to CVR Energy’s financial decision-making and investor...

Pebblebrook Hotel Trust (NYSE:PEB) was recently added to the Russell 2000 Defensive Index and the Russell 2000 Value-Defensive Index, while keeping its quarterly common dividend at US$0.01 per share. This dual index inclusion enhances the REIT’s profile among institutional and rules-based investors, potentially reinforcing its positioning as a value-oriented, defense-tilted hotel owner. Next, we’ll explore how Pebblebrook’s shift into the Russell 2000 Defensive framework may influence its...

Founder led companies can be especially interesting when inflation, interest rates and geopolitical risks keep shifting, because the people in charge often have more at stake than just their pay package. This Founder-Led Companies screener focuses on leaders who are deeply invested in the long term outcome of their business, at a time when energy prices, central bank moves and global trade tensions keep markets on edge. In this article, you will see three stocks from the screener that show...

On 27 June 2026, Phillips Edison & Company, Inc. (NasdaqGS: PECO) was removed from multiple Russell growth and small-cap benchmarks, including the Russell 2000 Growth and Russell 3000 Growth indices. This broad index removal can influence how passive funds and benchmark-focused investors view and trade Phillips Edison, potentially affecting liquidity and ownership mix. We’ll now examine how Phillips Edison’s removal from several Russell growth indices might influence its existing investment...

On June 27, 2026, Veralto Corporation (NYSE: VLTO) was removed from several Russell growth-oriented benchmarks, including the Russell Midcap Growth, Russell 1000 Growth, Russell 3000 Growth, Russell 3000E Growth, and Russell 1000 Growth-Defensive indexes. This broad index removal matters because it can prompt index-tracking funds and some institutional investors to adjust their holdings, potentially shifting trading volumes and liquidity around Veralto shares. Next, we will examine how...

In late June 2026, Core & Main, Inc. (NYSE:CNM) was removed from multiple Russell growth benchmarks, including the Russell 1000 Growth, 3000E Growth, 2500 Growth, Midcap Growth, and Small Cap Comp Growth indices. This broad index removal could reshape the company’s investor base and trading patterns as funds tracking these benchmarks adjust their Core & Main holdings. We’ll now explore how Core & Main’s removal from several Russell growth indices may affect its previously outlined investment...

In recent months, analysts have highlighted that First Commonwealth Financial’s long-term revenue and earnings trends lag sector benchmarks, even as the bank has delivered comparatively strong short-term performance and modest improvements in tangible book value expectations. Commentary now suggests that, despite a business model focused on diversification and efficiency, the company may offer less compelling growth potential than some alternative opportunities in other industries. Next,...

MillerKnoll, Inc. recently reported past fourth-quarter and full-year 2026 results showing higher sales of US$1,004.2 million and US$3.84 billion respectively, alongside a move from losses to net income and positive earnings per share from continuing operations. The company also issued fiscal 2027 guidance calling for US$928 million–US$968 million in first-quarter sales and US$3.93 billion–US$4.13 billion for the full year, signaling expectations for higher revenue with gross margins...

In late June 2026, BioLife Solutions, Inc. (NasdaqCM: BLFS) was added to multiple Russell value-oriented benchmarks, including the Russell 2000 Value, 2500 Value, 3000 Value, 3000E Value, Microcap Value, and Small Cap Comp Value indices. This broad index inclusion enhances BioLife Solutions’ visibility with institutional investors and index-tracking funds, potentially affecting liquidity, ownership mix, and how the market assesses its role within the cell and gene therapy ecosystem. Next,...